中国肺癌杂志2017，Vol.20Issue(5)：352-360,9.DOI:10.3779/j.issn.1009-3419.2017.05.09
非小细胞肺癌新辅助治疗联合外科治疗的进展
Progress of Neoadjuvant Therapy Combined with Surgery in Non-small Cell Lung Cancer
摘要
Abstract
Background and objective Lung cancer is the leading form of cancer in terms of both incidence and cancer-related deaths. For patients with resectable Ⅲa/N2 non-small cell lung cancer (NSCLC), guidelines in and abroad recommend multidisciplinary team treatment, including surgery and chemotherapy, radiotherapy or other comprehensive treatment. Newly published evidences prove that neoadjuvant therapy can improve outcomes of NSCLC patients significantly, with advangtages in tolerability and compliance medication. Neoadjuvant therapy has been adopted mainly in locally advanced NSCLC, especially in stages Ⅲa/N2 patients, and chemotherapy of 2-4 cycles has become the basic pattern. Neoadjuvant therapy does not increase the concomitant complications of chemotherapy and surgery. However, challenges still exist in deter-mining subsequent surgical timing, approach and extent of resection.关键词
肺肿瘤/新辅助治疗/手术Key words
Lung neoplasms/Neoadjuvant therapy/Surgery引用本文复制引用
王亚旗,王兴,阎石,杨跃,吴楠..非小细胞肺癌新辅助治疗联合外科治疗的进展[J].中国肺癌杂志,2017,20(5):352-360,9.基金项目
本文受北京市医院管理局临床医学发展专项经费资助(No.ZYLX201509)、北京市科学技术委员会(No.Z161100000516063)资助 This work was supported by Beijing Municipal Administration of Hospitals Clinical medicine Development of spe-cial funding support (to Yue YANG)(No.ZYLX201509) and Beijing Municipal Science & Technology Commission (to Nan WU)(No.Z161100000516063). （No.ZYLX201509）
